Evidence map›Paper›PMID 36917217›Full record

Trial reportInflammation research : official journal of the European Histamine Research Society ... [et al.]2023

Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patients.

N B Amaral, T S Rodrigues, M C Giannini, M I Lopes, L P Bonjorno, P I S O Menezes, S M Dib, S L G Gigante, M N Benatti, U C Rezek and 24 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 1 institution in 1 country.

N B AmaralDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14.048-900, São Paulo, Brazil.
T S RodriguesDepartment of Cell Biology, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
M C GianniniDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14.048-900, São Paulo, Brazil.
M I LopesDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14.048-900, São Paulo, Brazil.
L P BonjornoDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14.048-900, São Paulo, Brazil.
P I S O MenezesDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14.048-900, São Paulo, Brazil.
S M DibDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14.048-900, São Paulo, Brazil.
S L G GiganteDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14.048-900, São Paulo, Brazil.
M N BenattiDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14.048-900, São Paulo, Brazil.
U C RezekDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14.048-900, São Paulo, Brazil.
L L Emrich-FilhoDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14.048-900, São Paulo, Brazil.
B A SousaDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14.048-900, São Paulo, Brazil.
S C L AlmeidaDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14.048-900, São Paulo, Brazil.
R Luppino-AssadDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14.048-900, São Paulo, Brazil.
F P VerasDepartment of Pharmacology, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
A H SchneiderDepartment of Pharmacology, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
L O S LeiriaDepartment of Pharmacology, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
L D CunhaDepartment of Cell Biology, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
J C Alves-FilhoDepartment of Pharmacology, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
T M CunhaDepartment of Pharmacology, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
E ArrudaDepartment of Cell Biology, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
C H MirandaDepartment of Emergency Medicine, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
A Pazin-FilhoDepartment of Emergency Medicine, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
M Auxiliadora-MartinsDepartment of Surgery and Anatomy, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
M C BorgesDepartment of Emergency Medicine, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
B A L FonsecaDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14.048-900, São Paulo, Brazil.
V R BollelaDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14.048-900, São Paulo, Brazil.
C M Del-BenDepartment of Neuroscience and Behavior Ribeirao Preto Medical School, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
F Q CunhaDepartment of Pharmacology, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
R C SantanaDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14.048-900, São Paulo, Brazil.
F C VilarDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14.048-900, São Paulo, Brazil.
D S ZamboniDepartment of Cell Biology, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
P Louzada-JuniorDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14.048-900, São Paulo, Brazil.
R D R OliveiraDepartment of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14.048-900, São Paulo, Brazil. renedroliveira@gmail.com.
Universidade de São Paulo · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 425075/2016-8Fundação de Amparo à Pesquisa do Estado de São Paulo 2013/08216-2Fundação de Amparo à Pesquisa do Estado de São Paulo 2020/04826-4Fundação de Amparo à Pesquisa do Estado de São Paulo 2020/04964-8Fundação de Amparo à Pesquisa do Estado de São Paulo 2020/05288-6
6 · The paper itself

Abstract

objectiveTo evaluate whether colchicine treatment was associated with the inhibition of NLRP3 inflammasome activation in patients with COVID-19.

methodsWe present a post hoc analysis from a double-blinded placebo-controlled randomized clinical trial (RCT) on the effect of colchicine for the treatment of COVID-19. Serum levels of NOD-like receptor protein 3 (NLRP3) inflammasome products-active caspase-1 (Casp1p20), IL-1β, and IL-18-were assessed at enrollment and after 48-72 h of treatment in patients receiving standard-of-care (SOC) plus placebo vs. those receiving SOC plus colchicine. The colchicine regimen was 0.5 mg tid for 5 days, followed by 0.5 mg bid for another 5 days.

resultsThirty-six patients received SOC plus colchicine, and thirty-six received SOC plus placebo. Colchicine reduced the need for supplemental oxygen and the length of hospitalization. On Days 2-3, colchicine lowered the serum levels of Casp1p20 and IL-18, but not IL-1β.

conclusionTreatment with colchicine inhibited the activation of the NLRP3 inflammasome, an event triggering the 'cytokine storm' in COVID-19. TRIAL REGISTRATION NUMBERS: RBR-8jyhxh.

Indexed as

COVID-19InflammasomesColchicineHumansInterleukin-18Interleukin-1betaNLR Family, Pyrin Domain-Containing 3 ProteinNLR ProteinsColchicineInflammasomesInterleukin-18Interleukin-1betaNLR Family, Pyrin Domain-Containing 3 ProteinNLR ProteinsColchicineCOVID-19CytokinesInflammasome

Identifiers

PMID36917217
PMCPMC10013297
OpenAlexW4324129513

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.